Under the terms of the agreement , Purdue will pay Transcept near-term milestones that include an upfront cash payment of $ 25 million and an additional payment of up to $ 30 million based upon the timing of an FDA approval of Intermezzo ( ( R ) ) , which approval and payment are subject to review and acceptance by Purdue . Transcept is eligible to receive up to an additional $ 90 million upon reaching future milestones related to achievement of intellectual property and U.S. net sales targets .